{"name":"Vicore Pharma AB","slug":"vicore-pharma-ab","ticker":"","exchange":"","domain":"vicorepharmaab.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Buloxibutid","genericName":"Buloxibutid","slug":"buloxibutid","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"C21","genericName":"C21","slug":"c21","indication":"Advanced solid tumors (in combination with checkpoint inhibitors)","status":"phase_3"}]}],"pipeline":[{"name":"Buloxibutid","genericName":"Buloxibutid","slug":"buloxibutid","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"C21","genericName":"C21","slug":"c21","phase":"phase_3","mechanism":"C21 is a CD40 agonist that activates the CD40 receptor on immune cells to enhance anti-tumor immune responses.","indications":["Advanced solid tumors (in combination with checkpoint inhibitors)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxORTdUTF96MlVaeVduenA3dTJyRTVoeHhjaTdMaG0tOW00THdWdE0zWWdMekYwWGxiRHRmaVQ4UDliNnUwb3d1SUl0ajB3X0RQY2RNY3NLakxGNDZ0cXJ0LVhKd041WnFmWjNUVkZ0c2xIbWotamh5bEhEOGJJX2t2UG1BSWhvY0RLU1NOWTktV1hSNGY2a1QzQnF1bU4teHNnQ20wMzFfaG1ET3BMQU8wS1FfZUdRalBhODFycHRSOXk?oc=5","date":"2026-04-01","type":"pipeline","source":"TipRanks","summary":"Vicore Pharma Calls 2026 AGM With Capital and Incentive Plans on Agenda - TipRanks","headline":"Vicore Pharma Calls 2026 AGM With Capital and Incentive Plans on Agenda","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOU3dZbGpzc05La2ZURTgtS2kyX3h0QkhxNmI2T2p3MUxQWmYweW9pV2hnU0FyOWV5b0FyTUJjc2ZNQmg0VkUzTTVoOUZLTDk1MVc0RzRiRlNidzJWdEdlWmxwdFgtV0txaC0xcjhpeFFlcXVyYy1zTjJ2cnBRYmJRS3pkZjdtNkctOW53SngtSmdvWENHT29uaGNYRUNycy1YUVMxdlRzMDEzX2x5SzZ5aGYwN0NmS1hTRXo2X2ctVThEamdiUGdDN1dMTWhiQ00?oc=5","date":"2026-03-09","type":"pipeline","source":"TipRanks","summary":"Vicore Pharma Targets Investor Visibility With Back-to-Back Healthcare Conferences - TipRanks","headline":"Vicore Pharma Targets Investor Visibility With Back-to-Back Healthcare Conferences","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-26","type":"pipeline","source":"simplywall.st","summary":"individual investors who own 44% along with institutions invested in Vicore Pharma Holding AB (publ) (STO:VICO) saw increase in their holdings value last week - simplywall.st","headline":"individual investors who own 44% along with institutions invested in Vicore Pharma Holding AB (publ) (STO:VICO) saw incr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQZGlKMnZlWU00REYyVWtGQVdtWExwbFZWUGI4TXdNakp2cTNvT1k5SnpiNWdqV0RpblRUbHc5blc1WkltRUcxVlFIYXFjWUREZ0ROZGkzSTltWDRWYUxvWDVGNDR0OEs2SkF1SXhTcWZDYzFkRXNyVlJEWFlhNUZQVWp4ZHVLTFhQb3UzdGp5SlJ6a3J4cnBVY0V4bWNwTURILTFlbGtHTWVSYzgyMnBySmtpN3owMnJ5bHpkanNvSTFUajFhbU05U3o4QWpPUm5aNzlVYXFVX3o4NER5QVE?oc=5","date":"2025-06-30","type":"pipeline","source":"Finansavisen","summary":"Increase in number of shares and votes in Vicore Pharma - Finansavisen","headline":"Increase in number of shares and votes in Vicore Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBrV0pRUWxHa0U1ZVE2N1ZycVJlUkFtZWlibkJ5Ykxrbl9kNkltM25HOW92enNPckFkYnB3Zk5mWnlwU2lydWpIOEcyQk5VUkoyeTczdDJmbEN3dXhwZUJseGF0Q2dYXzFh?oc=5","date":"2023-05-12","type":"pipeline","source":"TradingView","summary":"VICO Forecast — Price Target — Prediction for 2027 - TradingView","headline":"VICO Forecast — Price Target — Prediction for 2027","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQeU9qV1EyR0FFaXpJMGJiWXdTY2RKWWNFdmtDaW9HZVdXWGR6VmhIM0dBRDJDdGtlZ01zSUFESTlVSDJkV182TWdrUzJUQ0l4UmItb0FscG1CZU5VdnFtU1VCcnNZNFZDVTFzRWNnczFCTkN6Z0hCLUVtVnNqYk9Gck5aT3lvNGFrMVIxVUpvRzI?oc=5","date":"2020-08-21","type":"pipeline","source":"marketscreener.com","summary":"Vicore Pharma Holding AB: Target Price Consensus and Analysts Recommendations | VICO | SE0007577895 - marketscreener.com","headline":"Vicore Pharma Holding AB: Target Price Consensus and Analysts Recommendations | VICO | SE0007577895","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPQlpSTEZBaGtsdUJDWFRGdlZ0YU9aZkU3OHcycV8zS0lZNkdBXzlwd2VSUjB4YldibGRWSlBTVmRsOFBZYkp4dWpWcGJ1cGtZYXBzWWVsVmU5b1BRcElWNkdHR0wzMEgtc0FoY091NjFxcjBUalFkS29yTnlRb1o1ZFZSNA?oc=5","date":"2020-08-18","type":"pipeline","source":"marketscreener.com","summary":"Vicore Pharma Holding AB Stock (VICO) - Quote Nasdaq Stockholm - marketscreener.com","headline":"Vicore Pharma Holding AB Stock (VICO) - Quote Nasdaq Stockholm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTFBYampVaHV0SGRySDhNSV9zaXVZZXJBNm8xbnR2eXRQY25JUTJCZDdfVVdBdmhGOGtyZ2k5WEY5YmRWQmNic3dRdjBEVk1JUzZqSXJHcFBOaWVJY2RDTzE0X2JLQTZxN3BYVVFn?oc=5","date":"2018-05-29","type":"pipeline","source":"TradingView","summary":"Technical Analysis of Vicore Pharma Holding AB (OMXSTO:VICO) - TradingView","headline":"Technical Analysis of Vicore Pharma Holding AB (OMXSTO:VICO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE1BQ2VTOXlQZmg0NXc3cTFzcWNpYjNTZ19aWmRWNGNONFY0VjdhY0dibURUSHotczFlWDBZNUdnODVBOGJpVnZiWkEyWHlYLThzT0dwUWZob0VhX3Z6?oc=5","date":"2018-04-14","type":"pipeline","source":"TradingView","summary":"VICO Stock Price and Chart — OMXSTO:VICO - TradingView","headline":"VICO Stock Price and Chart — OMXSTO:VICO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNMC00alN3WndTOVdia2Y3Q1lJclNMdEo3Y3VuMTQ0WUdUeklSSXlYY3dPM0h2UTJhckhxS0hLYUtQZE5NNG4zVk5naExja3A3eXRJUm1ONl80MGhGZUtGckVRZDZ4SGRac0NScF9tN3dYN21QelVsQk1EZllRb0FjZ3RZUzhMM3pVRjNRSDNVZFRfTEpCOW5NcGh5X2h3SGRScS11ZFVpNnJJUQ?oc=5","date":"2016-11-09","type":"trial","source":"Mynewsdesk","summary":"Phase I-study succesfully completed - Mynewsdesk","headline":"Phase I-study succesfully completed","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}